| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 01/08/2004 | WO2004003215A1 Method of isolating biologically active fraction containing clinically acceptable native slipopolysaccharides obtained from bacteria producing endotoxic lipopolysaccharides |
| 01/08/2004 | WO2004003198A1 Method of examining allergic disease and drug for treating the same |
| 01/08/2004 | WO2004003195A1 Tryptophan as a functional replacement for adp-ribose-arginine in recombinant proteins |
| 01/08/2004 | WO2004003185A2 Plant deoxyribonucleoside kinase enzymes and their use |
| 01/08/2004 | WO2004003166A2 Antibodies and uses thereof |
| 01/08/2004 | WO2004003164A2 Methods of organ regeneration |
| 01/08/2004 | WO2004003007A1 Non-t cell binding peptides and their uses |
| 01/08/2004 | WO2004002961A1 Caspase inhibitors and uses thereof |
| 01/08/2004 | WO2004002960A1 Substituted quinoline ccr5 receptor antagonists |
| 01/08/2004 | WO2004002948A1 Amide compound and medicinal use thereof |
| 01/08/2004 | WO2004002533A1 Stable liquid parenteral parecoxib formulation |
| 01/08/2004 | WO2004002528A1 Compositions and methods for therapeutic treatment |
| 01/08/2004 | WO2004002511A1 Anti-hiv agent |
| 01/08/2004 | WO2004002506A1 Agent for curing anaphlactic disease and health food, and manufacturing process thereof |
| 01/08/2004 | WO2004002505A1 Compositions against inflammatory processes |
| 01/08/2004 | WO2004002501A1 Antiallergic agent, utilization thereof for reducing allergy and method of reducing allergy |
| 01/08/2004 | WO2004002500A1 Method of treating autoimmune diseases with interferon-beta and il-2r antagonist |
| 01/08/2004 | WO2004002484A1 Phosphodiesterase inhibitor |
| 01/08/2004 | WO2004002424A2 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 01/08/2004 | WO2004002421A2 Method for the treatment of multiple sclerosis |
| 01/08/2004 | WO2004002420A2 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use |
| 01/08/2004 | WO2004002367A1 Drug eluting stent |
| 01/08/2004 | WO2003090912A9 Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
| 01/08/2004 | WO2003090665A3 Regulation of erythrocyte apoptosis |
| 01/08/2004 | WO2003087174A3 Carbocyclic and oxacarbocyclic fumaric acid oligomers |
| 01/08/2004 | WO2003086315A3 Tyrosine kinase inhibitors |
| 01/08/2004 | WO2003078614A3 Gntiii (udp-n-acethylglucosamine:beta-d mannoside beta (1,4)-n-acethylglucosaminy ltransferase iii) expression in plants |
| 01/08/2004 | WO2003070969A3 RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 01/08/2004 | WO2003070166A3 Novel tyloindicines and related processes, pharmaceutical compositions and methods |
| 01/08/2004 | WO2003068812A3 Immune-modulating peptide made of s. aureus enterotoxin b |
| 01/08/2004 | WO2003063766A3 Novel immunogenic compositions for the prevention and treatment of meningococcal disease |
| 01/08/2004 | WO2003047618A3 Immunotherapeutic methods and systems |
| 01/08/2004 | WO2003043648A3 Sfcyr iib or sfcyr iii for the treatment of auto-immune diseases |
| 01/08/2004 | WO2003039382A3 System for processing tissue |
| 01/08/2004 | WO2003020876A3 Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
| 01/08/2004 | WO2003000859A3 G-protein coupled receptors |
| 01/08/2004 | WO2002095067A3 INTERFERON α-14 POLYMORPHISM |
| 01/08/2004 | WO2002092075A3 Therapeutic delivery of carbon monoxide |
| 01/08/2004 | WO2002091996A3 Methods for treating cancer |
| 01/08/2004 | WO2002080952A3 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways |
| 01/08/2004 | WO2002079448A3 G-protein coupled receptors |
| 01/08/2004 | WO2002078624A3 Aerosol administration of interleukin-2 liposomes |
| 01/08/2004 | WO2002053522A3 Novel estrogen receptor ligands and methods i |
| 01/08/2004 | WO2002053130A3 Sustained release drug delivery devices with coated drug cores |
| 01/08/2004 | WO2002050250A3 Signal-1/signal-2 bifunctional peptide inhibitors |
| 01/08/2004 | WO2002048397A3 Regulation of human adenylate cyclase, type vii |
| 01/08/2004 | WO2002045737A3 Methods of treatment involving human mda-7 |
| 01/08/2004 | US20040006242 Immunomodulatory compounds and method of use thereof |
| 01/08/2004 | US20040006216 Comprises immunoglobulin for treating cancer; immunosuppressant; immunotherapy |
| 01/08/2004 | US20040006215 Human monoclonal antibodies against CD30 |
| 01/08/2004 | US20040006208 Comprises three-dimensional structure of bound immunoglobulin complex; antiinflammatory/anticarcinogenic; viricides |
| 01/08/2004 | US20040006207 Comprises ligand polypeptide for treatment of viral infection and prevention of immunological response; immunosuppressants; genetic vaccines |
| 01/08/2004 | US20040006205 Comprises g-protein coupled receptor polypeptides for diagnosis, prevention and treatment of cancers, infections and dyslipidemias |
| 01/08/2004 | US20040006133 Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 01/08/2004 | US20040006123 Interleukin-4 gene expression inhibitors |
| 01/08/2004 | US20040006098 Induce cytokine biosynthesis in animals |
| 01/08/2004 | US20040006095 For therapy and prophylaxis of cardiovascular diseases, diabetes, diabetes- associated disorders, inflammatory diseases, immunological disorders, dermatological disorders, oncological disorders and central nervous system disorders |
| 01/08/2004 | US20040006083 Pyrazolopyrimidines as therapeutic agents |
| 01/08/2004 | US20040006081 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity |
| 01/08/2004 | US20040006080 Chemical compounds |
| 01/08/2004 | US20040006078 For therapy of autoimmune diseases, asthma, osteoporosis, atherosclerosis, Alzheimer's disease |
| 01/08/2004 | US20040006075 Benzoxazine and benzothiazine derivatives and the use thereof in medicaments |
| 01/08/2004 | US20040006067 Substituted piperidines and methods of use |
| 01/08/2004 | US20040006066 Ring fused pyrazole derivatives as CRF antagonists |
| 01/08/2004 | US20040006032 Vaccination |
| 01/08/2004 | US20040006022 For therapy of autoimmune or an inflammatory disease |
| 01/08/2004 | US20040006010 Compositions include a polynucleotide that is linked to an immunomodulatory molecule, which molecule comprises an antigen and may further comprise immunomodulators such as cytokines and adjuvants. The polynucleotide portion of the |
| 01/08/2004 | US20040005671 Immunointeractive molecules |
| 01/08/2004 | US20040005630 Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| 01/08/2004 | US20040005629 Natural ligand of orphan G protein coupled receptor GPR86 and methods of use |
| 01/08/2004 | US20040005588 Using DNA vaccines to treat and prevent insulin depentent diabetes mellitus |
| 01/08/2004 | US20040005576 Comprises polypeptides for diagnosing, prognosing and preventing cancer, nervous system, developmental and metabolic disorders |
| 01/08/2004 | US20040005545 Plasmid comprising heterologous viral gene sequences for diagnosis, prevention and treatment of respiratory system disorders; vaccine development; viricides |
| 01/08/2004 | US20040005338 Virus like particles (VLPs) can be loaded and packaged, respectively, with DNA oligonucleotides rich in non-methylated C and G (CpGs). If such CpG-VLPs are mixed with antigens, the immunogenicity of these antigens are |
| 01/08/2004 | US20040005318 Method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided. |
| 01/08/2004 | US20040005316 Use of HMG fragments as anti-inflammatory agents |
| 01/08/2004 | US20040005305 Nutritional composition for treating an immune condition |
| 01/08/2004 | US20040005299 Method for producing pseudo islets |
| 01/08/2004 | US20040005298 Compositions and methods for restoring immune responsiveness in patients with immunological defects |
| 01/08/2004 | DE10227269A1 Thiazolderivate Thiazole derivatives |
| 01/08/2004 | CA2844639A1 Method for the treatment of multiple sclerosis |
| 01/08/2004 | CA2493854A1 Phosphodiesterase inhibitor |
| 01/08/2004 | CA2493646A1 Caspase inhibitors and uses thereof |
| 01/08/2004 | CA2492066A1 Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 01/08/2004 | CA2491427A1 Compositions and methods for therapeutic treatment |
| 01/08/2004 | CA2491363A1 Antibodies and uses thereof |
| 01/08/2004 | CA2490804A1 Method of treating autoimmune diseases with interferon-beta and il-2r antagonist |
| 01/08/2004 | CA2490411A1 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 01/08/2004 | CA2490290A1 Tryptophan as a functional replacement for adp-ribose-arginine in recombinant proteins |
| 01/08/2004 | CA2490016A1 Probiotic strains, a process for the selection of them, compositions thereof, and their use |
| 01/08/2004 | CA2489560A1 Substituted quinoline ccr5 receptor antagonists |
| 01/08/2004 | CA2489376A1 Methods of organ regeneration |
| 01/08/2004 | CA2488526A1 Stable liquid parenteral parecoxib formulation |
| 01/08/2004 | CA2472438A1 Mannose binding protein for use in anti-hiv treatment |
| 01/07/2004 | EP1378573A1 Interleukin 1 beta protease and interleukin 1 beta protease inhibitors |
| 01/07/2004 | EP1378516A1 Mixture of recombinant vaccinia vectors as polyenv vaccines for HIV |
| 01/07/2004 | EP1378510A1 Triazaspiro 5.5]undecane derivatives and drugs containing the same as the active ingredient |
| 01/07/2004 | EP1378177A1 Vitamin-containing system for stabilising the immune response of animals |
| 01/07/2004 | EP1377671A2 Oncolytic adenoviral vectors |
| 01/07/2004 | EP1377663A2 Intermediates and enzymes of the non-mevalonate isoprenoid pathway |